# HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children

> **NCT00978068** · PHASE3 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 176 (actual)

## Conditions studied

- Malaria
- HIV Infections

## Interventions

- **DRUG:** Lopinavir/Ritonavir (LPV/r)
- **DRUG:** Nevirapine (NVP)
- **DRUG:** Efavirenz (EFV)
- **DRUG:** 2 nucleoside reverse transcriptase inhibitor (NRTI)

## Key facts

- **NCT ID:** NCT00978068
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2018-12-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00978068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00978068, "HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00978068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*